Merck & Co. Inc. (MRK)

84.48
0.88 1.03
NYSE : Health Technology
Prev Close 85.36
Open 85.98
Day Low/High 84.32 / 86.50
52 Wk Low/High 59.80 / 85.56
Volume 5.28M
Avg Volume 10.04M
Exchange NYSE
Shares Outstanding 2.57B
Market Cap 217.53B
EPS 2.30
P/E Ratio 49.12
Div & Yield 2.20 (2.47%)

Latest News

AstraZeneca And Merck's LYNPARZA® (olaparib) Approved In Japan As First-Line Maintenance Therapy In Patients With BRCA-Mutated Advanced Ovarian Cancer

AstraZeneca And Merck's LYNPARZA® (olaparib) Approved In Japan As First-Line Maintenance Therapy In Patients With BRCA-Mutated Advanced Ovarian Cancer

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has approved LYNPARZA as a maintenance treatment after first-line chemotherapy in patients...

LYNPARZA® (olaparib) Approved In The EU For Use As First-Line Maintenance Therapy In Patients With BRCA-Mutated Advanced Ovarian Cancer

LYNPARZA® (olaparib) Approved In The EU For Use As First-Line Maintenance Therapy In Patients With BRCA-Mutated Advanced Ovarian Cancer

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved LYNPARZA as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV)...

New Targets for Merck Stock as Charts Point Higher

New Targets for Merck Stock as Charts Point Higher

Investors and traders should approach MRK from the long side.

Market Outlook: Cramer's 'Mad Money' Recap (Friday 6/14/19)

Market Outlook: Cramer's 'Mad Money' Recap (Friday 6/14/19)

Jim Cramer's got the low-down on IPOs, the Fed, trade and more. Here's your game plan for next week's action.

How to Invest in Stocks: 14 Keys to Remember

How to Invest in Stocks: 14 Keys to Remember

Larry Swedroe lays out the fundamental truths of investing -- for beginners.

IBM, KPMG, Merck And Walmart To Collaborate As Part Of FDA's Program To Evaluate The Use Of Blockchain To Protect Pharmaceutical Product Integrity

IBM, KPMG, Merck And Walmart To Collaborate As Part Of FDA's Program To Evaluate The Use Of Blockchain To Protect Pharmaceutical Product Integrity

The FDA pilot program explores innovative and emerging approaches for the tracing and verification of prescription products

The 3 Things Jim Cramer Watches For When a Company Announces M&A Plans

The 3 Things Jim Cramer Watches For When a Company Announces M&A Plans

Jim Cramer weighs in on what he's watching when a company announces M&A plans.

FDA Approves Two New Indications For Merck's KEYTRUDA® (pembrolizumab)

FDA Approves Two New Indications For Merck's KEYTRUDA® (pembrolizumab)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.

Here's How I'm Playing Salesforce.com Stock Now

Here's How I'm Playing Salesforce.com Stock Now

I am no longer as eager to sell these shares as when I discussed this merger pre-opening.

Merck to Buy Tilos Therapeutics for Up to $773 Million

Merck to Buy Tilos Therapeutics for Up to $773 Million

Merck will buy Tilos Therapeutics, a privately held biopharmaceutical company, for up to $773 million.

Jim Cramer: What Merger Mania and a Trump Phone Call Mean for the Markets - LIVE

Jim Cramer: What Merger Mania and a Trump Phone Call Mean for the Markets - LIVE

Here's what Jim Cramer's watching in the markets, Raytheon and United Technology's merger and Salesforce and Merck's acquisitions.

Merck To Acquire Tilos Therapeutics

Merck To Acquire Tilos Therapeutics

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it has entered into a definitive agreement to acquire Tilos Therapeutics, a privately held biopharmaceutical company developing therapeutics targeting the latent...

FDA Approves Merck's ZERBAXA® (ceftolozane And Tazobactam) 3g Dose For The Treatment Of Adults With Hospital-Acquired And Ventilator-Associated Bacterial Pneumonia (HABP/VABP)

FDA Approves Merck's ZERBAXA® (ceftolozane And Tazobactam) 3g Dose For The Treatment Of Adults With Hospital-Acquired And Ventilator-Associated Bacterial Pneumonia (HABP/VABP)

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.

Kaplan-Meier Estimates Of PFS By Blinded, Independent Central Review (Graphic: Business Wire)

Kaplan-Meier Estimates Of PFS By Blinded, Independent Central Review (Graphic: Business Wire)

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced detailed results from the Phase 3 POLO trial evaluating LYNPARZA tablets as a first-line maintenance monotherapy for patients with germline BRCA-mutated...

Five-Year Survival Data For Merck's KEYTRUDA® (pembrolizumab) In Advanced Non-Small Cell Lung Cancer (NSCLC) From First KEYNOTE Trial At 2019 ASCO Annual Meeting

Five-Year Survival Data For Merck's KEYTRUDA® (pembrolizumab) In Advanced Non-Small Cell Lung Cancer (NSCLC) From First KEYNOTE Trial At 2019 ASCO Annual Meeting

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of five-year efficacy and safety data for KEYTRUDA, Merck's anti-PD-1 therapy, as monotherapy in patients with advanced non-small cell lung cancer...

Merck's KEYTRUDA® (pembrolizumab) Demonstrates Improved Overall Survival As First-Line Treatment Of Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma At Final Analysis Of Pivotal Phase 3 KEYNOTE-048 Trial

Merck's KEYTRUDA® (pembrolizumab) Demonstrates Improved Overall Survival As First-Line Treatment Of Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma At Final Analysis Of Pivotal Phase 3 KEYNOTE-048 Trial

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of the final analysis of the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, as monotherapy and in combination with...

Merck Announces Third-Quarter 2019 Dividend

Merck Announces Third-Quarter 2019 Dividend

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.

TheStreet Quant Rating: A- (Buy)